SCHEDULE: Octagon Capital Discloses 9.99% Stake in Precision BioSciences

Octagon Capital Advisors LP, along with its Master Fund and Ting Jia, reported a 9.99% beneficial ownership stake in Precision BioSciences, Inc. as of December 31, 2025.

Summary

• Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia collectively reported beneficial ownership of 2,328,485 shares of Precision BioSciences, Inc. common stock.
• This ownership represents 9.99% of the company's outstanding common shares.
• The reported stake includes 1,917,995 common shares directly held and 410,490 common shares issuable upon the exercise of warrants.
• A 'Blocker' provision in the warrants prevents the reporting persons from exercising them to the extent that their beneficial ownership would exceed 9.99% of the outstanding common shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Precision BioSciences, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it indicates significant institutional interest in Precision BioSciences, suggesting a vote of confidence from a sophisticated investor.

Positives

• Significant institutional investment from Octagon Capital Advisors LP and Octagon Investments Master Fund LP, indicating confidence in Precision BioSciences' prospects.
• The 9.99% stake suggests a substantial, long-term interest from a sophisticated investor without triggering immediate concerns about activist intentions, as stated in the filing.

Risks

• The 'Blocker' provision limits the reporting persons' ability to increase their stake beyond 9.99% through warrant exercise, which could restrict their potential for greater influence or further capital injection via warrants if desired.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Precision BioSciences, Inc.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G are common disclosures, reflecting investment firms taking significant positions in public companies. For a biotechnology company like Precision BioSciences, attracting institutional investors such as Octagon Capital Advisors can signal market confidence in its pipeline or strategic direction, aligning with broader trends of specialized funds investing in high-growth sectors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence and potentially attract further investment, positively impacting share price stability or growth.
• Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing explicitly states the stake is not for control purposes.

Key Dates

Recommendation

The filing indicates a significant institutional stake, which is generally a positive signal of investor confidence. However, as a routine disclosure of ownership without additional strategic or financial updates, it does not provide new information warranting a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future company performance and any further disclosures from this significant shareholder.

Keywords

Precision BioSciences, Octagon Capital Advisors, Octagon Investments Master Fund, Ting Jia, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Biotechnology, Institutional Investment